Targeting SOS1 overcomes resistance to imatinib independent of BCR–ABL, through SLC22A4-mediated imatinib uptake in CML (33). The gene discussed is SLC22A4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.